182 related articles for article (PubMed ID: 38418456)
21. The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63β upon transformation.
Ben Khalifa Y; Teissier S; Tan MK; Phan QT; Daynac M; Wong WQ; Thierry F
PLoS Pathog; 2011 Sep; 7(9):e1002256. PubMed ID: 21980285
[TBL] [Abstract][Full Text] [Related]
22. A Critical Role for p53 during the HPV16 Life Cycle.
Fontan CT; James CD; Prabhakar AT; Bristol ML; Otoa R; Wang X; Karimi E; Rajagopalan P; Basu D; Morgan IM
Microbiol Spectr; 2022 Jun; 10(3):e0068122. PubMed ID: 35608342
[TBL] [Abstract][Full Text] [Related]
23. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.
Zanier K; ould M'hamed ould Sidi A; Boulade-Ladame C; Rybin V; Chappelle A; Atkinson A; Kieffer B; Travé G
Structure; 2012 Apr; 20(4):604-17. PubMed ID: 22483108
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.
Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM
J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652
[TBL] [Abstract][Full Text] [Related]
25. Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.
Ricci-López J; Vidal-Limon A; Zunñiga M; Jimènez VA; Alderete JB; Brizuela CA; Aguila S
PLoS One; 2019; 14(3):e0213028. PubMed ID: 30875378
[TBL] [Abstract][Full Text] [Related]
26. GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers.
Zhou Y; Wei Y; Zhu J; Wang Q; Bao L; Ma Y; Chen Y; Feng D; Zhang A; Sun J; Nallar SC; Shen K; Kalvakolanu DV; Xiao W; Ling B
PLoS One; 2011; 6(7):e22065. PubMed ID: 21765936
[TBL] [Abstract][Full Text] [Related]
27. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
28. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.
Shai A; Nguyen ML; Wagstaff J; Jiang YH; Lambert PF
Oncogene; 2007 May; 26(23):3321-8. PubMed ID: 17130828
[TBL] [Abstract][Full Text] [Related]
29. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
[TBL] [Abstract][Full Text] [Related]
30. Association strength of E6 to E6AP/p53 complex correlates with HPV-mediated oncogenesis risk.
Ferraz MVF; Viana IFT; Coêlho DF; da Cruz CHB; de Arruda Lima M; de Luna Aragão MA; Lins RD
Biopolymers; 2022 Oct; 113(10):e23524. PubMed ID: 36281776
[TBL] [Abstract][Full Text] [Related]
31. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
32. Surface plasmon resonance imaging protein arrays for analysis of triple protein interactions of HPV, E6, E6AP, and p53.
Ro HS; Koh BH; Jung SO; Park HK; Shin YB; Kim MG; Chung BH
Proteomics; 2006 Apr; 6(7):2108-11. PubMed ID: 16493710
[TBL] [Abstract][Full Text] [Related]
33. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
Drews CM; Case S; Vande Pol SB
PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of small molecule human papillomavirus E6 inhibitors.
Malecka KA; Fera D; Schultz DC; Hodawadekar S; Reichman M; Donover PS; Murphy ME; Marmorstein R
ACS Chem Biol; 2014 Jul; 9(7):1603-12. PubMed ID: 24854633
[TBL] [Abstract][Full Text] [Related]
35. Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex.
Sailer C; Offensperger F; Julier A; Kammer KM; Walker-Gray R; Gold MG; Scheffner M; Stengel F
Nat Commun; 2018 Oct; 9(1):4441. PubMed ID: 30361475
[TBL] [Abstract][Full Text] [Related]
36. Identification of E6AP-independent degradation targets of HPV E6.
Vats A; Thatte J; Banks L
J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
[TBL] [Abstract][Full Text] [Related]
37. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
38. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
39. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
40. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.
Talis AL; Huibregtse JM; Howley PM
J Biol Chem; 1998 Mar; 273(11):6439-45. PubMed ID: 9497376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]